Blar i Discussion papers (SAM) på forfatter "Brekke, Kurt R."

Viser treff 1-10 av 10

    • Capital taxation and imperfect competition : ACE vs. CBIT 

      Brekke, Kurt R.; Pires, Armando José Garcia; Schindler, Dirk; Schjelderup, Guttorm (Discussion paper;32/14, Working paper, 2014-11)
      This paper studies the market and welfare effects of two main tax reforms – the Corporate Business Income Tax (CBIT) and the Allowance for Corporate Equity tax (ACE). Using an imperfect-competition model for a small open ...

    • Competing with precision: incentives for developing predictive biomarker tests 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;06/2022, Working paper, 2022-03)
      We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework ...

    • Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates? 

      Brekke, Kurt R.; Holmås, Tor Helge; Monstad, Karin; Straume, Odd Rune (DP SAM;3, Working paper, 2017)
      Competition among physicians is widespread, but compelling empirical evidence on the impact on service provision is limited, mainly due to lack of exogenous variation in the degree of competition. In this paper we exploit ...

    • Do Treatment Decisions Depend on Physicians` Financial Incentives? 

      Brekke, Kurt R.; Holmås, Tor Helge; Karin, Monstad; Straume, Odd Rune (Discussion paper;15/15, Working paper, 2015-07)
      We study whether and how physicians respond to financial incentives, making use of detailed register data on the health-care services provided to patients by general practitioners (GPs) in Norway over a six-year period ...

    • Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform 

      Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune (Discussion paper;11/15, Working paper, 2015-06)
      In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmaceutical market. For given prices, RP increases generic firms' expected profit, but since RP also stimulates price ...

    • Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform 

      Brekke, Kurt R.; Chiara, Canta; Luigi, Siciliani; Straume, Odd Rune (DP SAM;28/2018, Working paper, 2018-12)
      We study the impact of exposing hospitals in a National Health Service (NHS) to non-price competition by exploiting a patient choice reform in Norway in 2001. The reform facilitates a difference-in-difference research ...

    • The Price of Cost-effectiveness Thresholds 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;04/2023, Working paper, 2023)
      Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform decisions about access and reimbursement. We study how CE thresholds imposed by a health plan for granting reimbursement ...

    • Reference pricing with endogenous generic entry 

      Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune (Discussion paper;04/15, Working paper, 2015-03)
      In this paper we study the effect of reference pricing on pharmaceutical prices and expenditures when generic entry is endogenously determined. We develop a Salop-type model where a brand-name producer competes with generic ...

    • Socioeconomic Status and Physicians’ Treatment Decisions 

      Brekke, Kurt R.; Holmås, Tor Helge; Monstad, Karin; Straume, Odd Rune (Discussion paper;12/15, Working paper, 2015-06)
      This paper aims at shedding light on the social gradient by studying the relationship between socioeconomic status (SES) and provision of health care. Using administrative data on services provided by General Practitioners ...

    • Taking the competitor’s pill: when combination therapies enter pharmaceutical markets 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (DP SAM;19/2023, Working paper, 2023-11-22)
      We study the competitive effects of combination therapies in pharmaceutical markets, which crucially hinge on the additional therapeutic value of combinatory use of drugs and the therapeutic substitutability with the most ...